Novartis Ag (NVSEF) Cash & Current Investments (2009 - 2026)

Novartis Ag (NVSEF) has 16 years of Cash & Current Investments data on file, last reported at $100.0 million in Q1 2026.

• Quarterly Cash & Current Investments rose 370.27% year-over-year to $100.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $520.0 million (down 59.12% YoY) and the FY2025 annual result came in at $2.7 billion, up 901.47% from the prior year.
• Cash & Current Investments fell to $100.0 million in Q1 2026 per NVSEF's latest filing, from $2.7 billion in the prior quarter.
• The five-year high for Cash & Current Investments was $18.9 billion in Q4 2022, with the low at -$13.1 billion in Q2 2022.
• Average Cash & Current Investments over 5 years is $2.8 billion, with a median of $273.0 million recorded in 2024.
• Year-over-year, Cash & Current Investments sank 25672.55% in 2022 and jumped 908.6% in 2023.
• Novartis Ag's Cash & Current Investments stood at $18.9 billion in 2022, then slumped by 32.64% to $12.8 billion in 2023, then sank by 97.86% to $273.0 million in 2024, then surged by 901.47% to $2.7 billion in 2025, then sank by 96.34% to $100.0 million in 2026.
• Business Quant data shows NVSEF's Cash & Current Investments at $100.0 million in Q1 2026, $2.7 billion in Q4 2025, and $197.0 million in Q3 2025.